October 2021 in “Book Publisher International (a part of SCIENCEDOMAIN International)” This study explored a new treatment for Alopecia Areata, combining high negative pressure microdermabrasion with intralesional steroid injections, and compared its effects to steroid injections alone, although the abstract does not report specific outcomes.
In this case series, researchers reported scarring alopecia in six out of 450 patients (1.33%) treated with immune checkpoint inhibitors for metastatic melanoma, with all affected patients experiencing other immune-related adverse effects but continuing treatment with favorable cancer outcomes.
In this study, researchers reported a 1.33% prevalence of scarring alopecia among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, noting that hair loss did not require treatment discontinuation and seemed to coincide with favorable cancer outcomes.
January 2026 in “JPRAS Open” In this pilot study, PDLLA scalp microinjections showed improvement in physician-rated Global Aesthetic Improvement Scale scores over 12-24 weeks for 90% of patients with non-scarring alopecia, with no serious adverse events reported, although findings remain preliminary due to methodological limitations.
7 citations
,
January 2012 in “International Journal of Trichology” This article highlights differences in childhood alopecia areata compared to adult cases but reports no new clinical findings.
